ArticleOncotarget2015

Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.

Seiichi Okabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.